216 - A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of the Beta-lactamase inhibitor Xeruborbactam Alone and in Combination Meropenem in Healthy Adult Subjects

Thursday, October 20, 2022

12:15 PM – 1:30 PM US ET

Location: Hall B + C

Co-Author(s)

DG

David Griffith, n/a

Sr. Vice-President, Non-Clinical and Clinical Development
Qpex Biopharma
San Diego, California, United States
Jason Roberts, BPharm(Hons), PhD, FSHP, FISAC

Professor & NHMRC Practitioner Fellow
The University of Queensland
Brisbane, Queensland, Australia
SW

Steven Wallis, n/a

Head of Bioanalysis
University of Queensland
Brisbane, Queensland, Australia
MH

Maria Patricia Hernandez-Mitre, n/a

Postdoctoral Research Fellow
University of Queensland
Brisbane, Queensland, Australia
EM

Elizabeth Morgan, n/a

Sr. Vice-President, Clinical and Regulatory Operations
Qpex Biopharma
San Diego, California, United States
SG

Shawnee Gehrke, n/a

Clinical Research Associate
Qpex Biopharma
San Diego, California, United States
MD

Michael Dudley, n/a

CEO
Qpex Biopharma
San Diego, California, United States

Jeff Loutit, MBChB

Chief Medical Officer
Qpex Biopharma
San Diego, California, United States